FDA
-
-
-
-
-
-
-
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
-
-
-
-
-
-
-
Graphite Corp. (GRPH) Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

